Efficacy and Safety of Polymer-Free Ultrathin Strut Sirolimus-Probucol Coated Drug-Eluting Stents for Chronic Total Occlusions: Insights from the Coroflex ISAR 2000 Worldwide Registry

Table 4

Recommended duration of dual antiplatelet therapy during follow-up.

Variable	Patients, n (%)	<25 mm lesion length, n (%)	≥25 mm lesion length, n (%)	value
Number of patients	111 (100%)	49 (44.1%)	62 (55.8%)	—
DAPT duration in months	9.7 ± 2.8	9.8 ± 2.8	9.6 ± 2.9	0.773
1 month	1 (0.9%)	1 (2.0%)	0 (0.0%)	0.355
1–3 months	0 (0.0%)	0 (0.0%)	0 (0.0%)
3–6 months	0 (0.0%)	0 (0.0%)	0 (0.0%)
6 months	30 (27.0%)	11 (22.4%)	19 (30.4%)
>6–12 months	8 (7.2%)	4 (8.2%)	4 (6.5%)
12 months	50 (45.0%)	20 (40.8%)	30 (48.4%)
>12 months	0 (0.0%)	0 (0.0%)	0 (0.0%)
Unknown status	22 (19.8%)	13 (26.5%)	9 (14.5%)